Newsfeed
Real-time intelligence on synbio and synbio funding, regulatory milestones, deployments, and policy.
CEX Chromatography Reclaims Its Role in mAb Purification
Cation exchange chromatography is back at center stage as rising mAb titers overwhelm standard affinity capture purity thresholds.
Read →Child Dies in HuidaGene CRISPR Trial, China Transparency Under Fire
A child died in HuidaGene's CRISPR trial for Duchenne MD. China's investigator-led pathway kept it hidden for 15 months.
Read →Rotating Drum Bioreactor Hits 1.3 g/L mAb Titer
ENEA's rotating drum bioreactor hit 1.3 g/L mAb titer vs 0.71 g/L in stirred-tank — nearly doubling yield by solving oxygen transfer limits.
Read →Confluence Genetics' Cas-CLEAR Targets Cancer Cells
Confluence Genetics' Cas-CLEAR uses a non-editing CRISPR mechanism to destroy cells with specific genetic signatures.
Read →Aurora Therapeutics Folds 7 Months After Launch
Aurora Therapeutics scraps its lead custom CRISPR program and cuts staff just 7 months after launch, undercut by Beam Therapeutics.
Read →Allogene's cema-cel Wins RMAT and Fast Track for LBCL
FDA grants RMAT and Fast Track to Allogene's allogeneic CD19 CAR-T; Sail and J&J partner on in vivo CAR-T for autoimmune disease.
Read →ARPA-H Funds AEGIS $27.7M to Edit Childhood Immune Disorders
ARPA-H awards IGI-led AEGIS consortium $27.7M to build a platform for personalised in vivo gene editing in paediatric immune disorders.
Read →UIUC Base Editors Cut HTT Toxic Fragments in Mice
UIUC scientists screened 140+ base editors to disrupt HTT exon 13 splicing, reducing toxic fragments in Huntington's mouse models.
Read →ElevateBio Locks In 98% miv-cel Manufacturing Rate for Kyverna
ElevateBio and Kyverna sign commercial supply deal for miv-cel CAR T, citing a >98% clinical manufacturing success rate.
Read →AAV Base Editing Trial Kills Child After Ethics Failures
A six-year-old died from thrombotic microangiopathy 7 days after dual-AAV9 base editing for a nonfatal syndrome, Science reports.
Read →AI Designs CRISPR Nucleases 30% Divergent From Nature
Two studies use AI to redesign CRISPR nucleases, with one producing proteins ~30% divergent from natural Cas12 sequences.
Read →China Concealed Child's Death in Gene Editing Trial
A six-year-old died seven days after a brain-targeted base editing trial in Shanghai. The death was concealed from global registries.
Read →All G Enters US Market with Sub-5% Iron Lactoferrin
Australian startup All G enters the US with precision-fermented apo-lactoferrin at below 5% iron saturation, produced at 60,000-liter scale.
Read →UCSD Joins IGI as Fourth UC CRISPR Partner
UC San Diego joins IGI as its fourth UC partner, adding marine science and AMR drug discovery to a network backed by $80M+ in recent grants.
Read →IGI Adds UCSD as 4th UC Partner for CRISPR Expansion
UC San Diego joins IGI as its fourth UC partner campus, expanding CRISPR applications in ocean science, microbiome, and antimicrobial resistance.
Read →Immitra Bio Raises CHF 2.4M for In-Vivo Gene Editing
ETH Zurich spinout Immitra Bio closes CHF 2.4M pre-seed to develop mutation-agnostic in-vivo gene editing for inherited anemias.
Read →FDA Clears Casgevy CRISPR Therapy for Children Age 2+
FDA extends Casgevy's sickle cell indication to patients as young as 2, adding ~5,500 eligible American children.
Read →AI-Designed TnpB Hits 50% Editing in Human Cells
AI-designed SynTnpB enzymes hit 50% editing efficiency in human cells vs. 28% for natural TnpB, per Science study.
Read →AI-Designed CRISPR Nucleases Match Natural Enzymes in Cells
UC Berkeley team uses ESM Inverse Folding + evolution constraints to build synthetic nucleases at 72–83% sequence divergence from nature.
Read →ADM Scales Every's OvoPro via Precision Fermentation
ADM partners with Every to scale OvoPro egg protein via precision fermentation, as orders surge 550% year-over-year in early 2026.
Read →